Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation

Authors
Lee, So-RyoungLee, Young SooPark, Ji-SuckCha, Myung-JinKim, Tae-HoonPark, JunbeomPark, Jin-KyuLee, Jung-MyungKang, Ki-WoonShim, JaeminUhm, Jae-SunKim, JunKim, ChangsooKim, Jin-BaePark, Hyung WookJoung, BoyoungChoi, Eue-Keun
Issue Date
3월-2019
Publisher
YONSEI UNIV COLL MEDICINE
Keywords
Atrial fibrillation; non-vitamin K antagonist oral anticoagulant; drug labeling; dose
Citation
YONSEI MEDICAL JOURNAL, v.60, no.3, pp.277 - 284
Indexed
SCIE
SCOPUS
KCI
Journal Title
YONSEI MEDICAL JOURNAL
Volume
60
Number
3
Start Page
277
End Page
284
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/67179
DOI
10.3349/ymj.2019.60.3.277
ISSN
0513-5796
Abstract
Purpose: Label adherence for non-vitamin K antagonist oral anticoagulants (NOACs) has not been well evaluated in Asian patients with non-valvular atrial fibrillation (AF). The present study aimed to assess label adherence for NOACs in a Korean AF population and to determine risk factors of off-label prescriptions of NOACs. Materials and Methods: In this COmparison study of Drugs for symptom control and complication prEvention of AF (CODE-AF) registry, patients with AF who were prescribed NOACs between June 2016 and May 2017 were included. Four NOAC doses were categorized as on- or off-label use according to Korea Food and Drug Regulations. Results: We evaluated 3080 AF patients treated with NOACs (dabigatran 27.2%, rivaroxaban 23.9%, apixaban 36.9%, and edoxaban 12.0%). The mean age was 70.5 +/- 9.2 years; 56.0% were men; and the mean CHA(2)DS(2)-VASc score was 3.3 +/- 1.4. Only one-third of the patients (32.7%) was prescribed a standard dose of NOAC. More than one-third of the study population (n=1122, 36.4%) was prescribed an off-label reduced dose of NOAC. Compared to those with an on-label standard dosing, patients with an off-label reduced dose of NOAC were older (>= 75 years), women, and had a lower body weight (<= 60 kg), renal dysfunction (creatinine clearance <= 50 mL/min), previous stroke, previous bleeding, hypertension, concomitant dronedarone use, and anti-platelet use. Conclusion: In real-world practice, more than one-third of patients with NOAC prescriptions received an off-label reduced dose, which could result in an increased risk of stroke. Considering the high risk of stroke in these patients, on-label use of NOAC is recommended.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE